Business · 14/04/1994Updated: 10/15/2026 · 1 min read
Correction to Regulatory Review Period for Purposes of Patent Extension of Supprelin
Summary
The Food and Drug Administration (FDA) is correcting a notice with mathematical errors regarding the regulatory review period for Supprelin (histrelin acetate), a patent extension for which was announced in the Federal Register on June 2, 1992.
Original source language: Federal Register — Health and Human ServicesOpen original release →